Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

被引:23
作者
Moy, Beverly [1 ,4 ]
Rumble, R. Bryan [2 ]
Carey, Lisa A. [3 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Amer Soc Clin Oncol, Alexandria, VA USA
[3] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[4] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
关键词
D O I
10.1200/JCO.22.02807
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
引用
收藏
页码:1318 / +
页数:4
相关论文
共 5 条
[1]   Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations [J].
Brozek, J. L. ;
Akl, E. A. ;
Compalati, E. ;
Kreis, J. ;
Terracciano, L. ;
Fiocchi, A. ;
Ueffing, E. ;
Andrews, J. ;
Alonso-Coello, P. ;
Meerpohl, J. J. ;
Lang, D. M. ;
Jaeschke, R. ;
Williams, J. W., Jr. ;
Phillips, B. ;
Lethaby, A. ;
Bossuyt, P. ;
Glasziou, P. ;
Helfand, M. ;
Watine, J. ;
Afilalo, M. ;
Welch, V. ;
Montedori, A. ;
Abraha, I. ;
Horvath, A. R. ;
Bousquet, J. ;
Guyatt, G. H. ;
Schuenemann, H. J. .
ALLERGY, 2011, 66 (05) :588-595
[2]   Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer [J].
Modi, Shanu ;
Jacot, William ;
Yamashita, Toshinari ;
Sohn, Joohyuk ;
Vidal, Maria ;
Tokunaga, Eriko ;
Tsurutani, Junji ;
Ueno, Naoto T. ;
Prat, Aleix ;
Chae, Yee Soo ;
Lee, Keun Seok ;
Niikura, Naoki ;
Park, Yeon Hee ;
Xu, Binghe ;
Wang, Xiaojia ;
Gil-Gil, Miguel ;
Li, Wei ;
Pierga, Jean-Yves ;
Im, Seock-Ah ;
Moore, Halle C. F. ;
Rugo, Hope S. ;
Yerushalmi, Rinat ;
Zagouri, Flora ;
Gombos, Andrea ;
Kim, Sung-Bae ;
Liu, Qiang ;
Luo, Ting ;
Saura, Cristina ;
Schmid, Peter ;
Sun, Tao ;
Gambhire, Dhiraj ;
Yung, Lotus ;
Wang, Yibin ;
Singh, Jasmeet ;
Vitazka, Patrik ;
Meinhardt, Gerold ;
Harbeck, Nadia ;
Cameron, David A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01) :9-20
[3]   Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update [J].
Moy, Beverly ;
Rumble, R. Bryan ;
Come, Steven E. ;
Davidson, Nancy E. ;
Di Leo, Angelo ;
Gralow, Julie R. ;
Hortobagyi, Gabriel N. ;
Yee, Douglas ;
Smith, Ian E. ;
Chavez-MacGregor, Mariana ;
Nanda, Rita ;
McArthur, Heather L. ;
Spring, Laura ;
Reeder-Hayes, Katherine E. ;
Ruddy, Kathryn J. ;
Unger, Paul S. ;
Vinayak, Shaveta ;
Irvin, William J., Jr. ;
Armaghani, Avan ;
Danso, Michael A. ;
Dickson, Natalie ;
Turner, Sophie S. ;
Perkins, Cheryl L. ;
Carey, Lisa A. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) :3938-+
[4]   Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) [J].
Rugo, H. S. ;
Bardia, A. ;
Marme, F. ;
Cortes, J. ;
Schmid, P. ;
Loirat, D. ;
Tredan, O. ;
Ciruelos, E. M. ;
Dalenc, F. ;
Gomez Pardo, P. ;
Jhaveri, K. ;
Delaney, R. J. ;
Valdez, T. ;
Wang, H. ;
Verret, W. ;
Tolaney, S. M. .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S1386-S1386
[5]   Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].
Rugo, Hope S. ;
Bardia, Aditya ;
Marme, Frederik ;
Cortes, Javier ;
Schmid, Peter ;
Loirat, Delphine ;
Tredan, Olivier ;
Ciruelos, Eva ;
Dalenc, Florence ;
Pardo, Patricia Gomez ;
Jhaveri, Komal L. ;
Delaney, Rosemary ;
Fu, Olivia ;
Lin, Lanjia ;
Verret, Wendy ;
Tolaney, Sara M. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) :3365-+